ArticleBreast cancer (Tokyo, Japan)2023

An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.

Reiko Fukui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.